What's in Laboratoires Mayoly Spindler's pipeline?

Laboratoires Mayoly Spindler has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Laboratoires Mayoly Spindler's portfolio?

Top competitors by shared drug class: Keimyung University Dongsan Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/laboratoires-mayoly-spindler.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Laboratoires Mayoly Spindler — Portfolio Competitive Intelligence Brief

Laboratoires Mayoly Spindler pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area
alverine citrate, simeticone	alverine citrate, simeticone	marketed
anti spasmodic agents	anti spasmodic agents	marketed	Antispasmodic agent	Gastroenterology
alverine citrate and simeticone	alverine citrate and simeticone	marketed	Antispasmodic/anti-foaming combination	Gastroenterology

Therapeutic area mix

Gastroenterology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Keimyung University Dongsan Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Laboratoires Mayoly Spindler:

Cite this brief

Drug Landscape (2026). Laboratoires Mayoly Spindler — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/laboratoires-mayoly-spindler. Accessed 2026-05-16.